We believe that the Swedish Armed Forces being the end-customer in the Teracom PoC is a positive, as...
Redeye is positive about the acquisition of Rosetta Capital’s shares in the investment vehicle KDev ...
Railcare presterar bra i väntan på nya uppdrag och trots kursuppgången de tre senaste månaderna finn...
Flughafen Wien’s May traffic data were better than feared and support our positive stance on the sto...
Bittium announced another order from the Finnish Defence Forces, worth of EUR 7m in total to be deli...
Solwers estimates that its performance in H1 2026 has developed weaker than expected and withdraws i...
Cereno Scientific has strengthened CS1’s commercial positioning with a third Canadian patent, extend...
SynAct has reported top-line results from its Phase IIb ADVANCE study evaluating resomelagon in newl...
Redeye provides an initial comment on BioVica’s Q4 2025/2026 report.
B&C raised its stake by 6.1pp to 63.4% via a € 15/share offer.
Aiforia agrees non-binding EIB term sheet for up to €20m venture debt, materially de-risking the fun...
We expect a Q2 characterised by an ongoing transition, including recently announced cost savings, wh...
We foresee strong PFPM/share growth in Q2, up 27% y/y (c.
InCoax has announced a SEK 11.2m directed share issue alongside an expanded credit facility, further...
* Q2e: 13% organic sales growth, 4.5% EBITA margin * We raise opex on increased competition * Tradin...
Cicor announced this morning it is divesting its Tunisian production facility which will close in Ju...
We update our base case after having analysed the ADVANCE data.
Apotea är Sveriges ledande nätapotek med en dominant marknadsposition och fortsatt potential för til...
* Infrea and Netel to merger * The combined company to have ~SEK 5bn in revenue * Stynnergies of ~SE...
Systemair avslutar 2025/26 starkt med hög organisk tillväxt, förbättrad lönsamhet men svagare kvarta...
